This evidence provided for the first time by the present study should, however, be further investigated to uncover the role of BCL-xL in the pathogenesis of pancreatic ductal adenocarcinoma, along with its potential role as a prognostic marker and a potential drug target—of course. The gene discussed is BCL2L1; the disease is pancreatic ductal adenocarcinoma.